Targeting CD38 by isatuximab and a CD38/CD3xCD28 trispecific T-cell engager in old patients with acute myeloid leukemia.
Martin-Sanchez E, Blanco Fernández L, Kim PS, Bisht K, Wang H, Van de Velde H, Jelinek T, Simoes C, Prosper F, San-Miguel JF, Alfonso A, Bergua Burgues JM, Rodríguez-Veiga R, Vives S, Martínez-Cuadrón D, Montesinos P, Paiva B, Zabaleta A.
Martin-Sanchez E, et al. Among authors: kim ps.
Blood Adv. 2024 May 30:bloodadvances.2024013212. doi: 10.1182/bloodadvances.2024013212. Online ahead of print.
Blood Adv. 2024.
PMID: 38815228
No abstract available.